FeesSafety
Pluang+

Forgent Power Solutions posts 89% revenue jump, $3B backlog amid AI data center boom

Company Fundamentals
15 Sep 2026
Seeking Alpha
View Source
Bullish
Forgent Power Solutions posts 89% revenue jump, $3B backlog amid AI data center boom

Forgent Power Solutions (FPS), a data center power distribution provider, reported an 89% year-over-year revenue increase to $1.42 billion for fiscal year 2026, driven by strong demand for modular solutions amid the AI buildout cycle. The company also saw a 375% rise in Q4 bookings and reached a record $3 billion backlog. FPS projects 69% revenue growth to $2.4–$2.6 billion and 86% EBITDA growth for fiscal year 2027, with valuation multiples now more reasonable. The strong execution and niche market position make FPS an attractive buy with a target price of $35.

Forgent Power Solutions' recent earnings report shows strong growth projections. For readers following the Technology sector, here is Pluang's market snapshot as of Sep 15, 2026 21:21 WIB: Of 150 priced US Technology stocks tradable on Pluang, 50 rose and 96 fell today. Notable movers include HPE at USD 57.32 (+3.45%), HOOD at USD 110.39 (-3.45%), and SNOW at USD 321.32 (-3.32%).

More News

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
46 minutes ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
46 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
46 minutes ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
1 hour ago
Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem Corporation reported strong Q3 2026 results with net sales of $290.7 million, up 8.6% year-over-year, and net earnings of $46.7 million, a 16% increase. Growth was driven by all three segments: Human Nutrition and Health, Animal Nutrition and...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App